Contrast-enhanced ultrasound: State of the art in North America

Contrast-enhanced ultrasound: State of the art in North America

Barr RG;Wilson SR;Lyshchik A;McCarville B;Darge K;Grant E;Robbin M;Wilmann JK;Chong WK;Fleischer A;Paltiel HJ

Ultrasound Quarterly

2020

2020-09

The Society of Radiologists in Ultrasound convened a panel of specialists in contrast-enhanced ultrasound (CEUS) to produce a white paper on noncardiac CEUS in North America. The panel met in Chicago, Illinois, on October 24 and 25, 2017. The recommendations are based on analysis of current literature and common practice strategies and are thought to represent a reasonable approach to introduce the advantages of this safe and noninvasive technique for the benefit of our patients. Characterization of liver nodules, and pediatric vascular and intravesicular applications comprise the approved indications for CEUS in the United States. They, along with the very successful off-label use of CEUS for the kidney, are included in this publication.Other off-label uses are presented with emphasis on their value and literature support in the online version.

safety; ultrasound contrast agents; AP = arterial phase; APHE = arterial phase hyperenhancement; CEUS = contrast-enhanced ultrasound; FLL = focal liver lesion; FNH = focal nodular hyperplasia; kidney masses; lesion characterization; liver masses; UCA = ultrasound contrast agent; ultrasound contrast

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

journalArticle

206-217

3

36

1536-0253 0894-8771

NEOMED College of Medicine

Department of Radiology

September 2020 List

Mercy Health St Elizabeth Boardman Hospital